3400 - A Prospective Study of CT-Guided and 3D-Printing Template-Assisted Implantation of Fiducial Markers in the Pancreatic Carcinoma for Stereotactic Body Radiation Therapy (FIRST-1 Study)
Presenter(s)
Y. Chen, Z. Ji, R. Lei, Y. Jiang, B. Qiu, M. Li, J. Li, and J. Wang; Department of Radiation Oncology, Peking University Third Hospital, Beijing, China
Purpose/Objective(s): Stereotactic body radiation therapy (SBRT) for the pancreatic carcinoma requires the implantation of fiducial markers for detection. This study aims to evaluate the feasibility of a new method of CT-guided and 3D-printing template-assisted implantation of fiducial marker and the appropriate time interval between the fiducial marker implantation and the CT simulation.
Materials/Methods: A single center and prospective clinical study (ChiECRCT20220033) (FIRST-1 trial) are proposed in this center and 10 pancreatic carcinoma patients who underwent CT-guided and 3D-printing template-assisted implantation of fiducial markers between 2021 and 2022 were enrolled. The success rate and safety of this new method were evaluated. CT simulations were performed on day 1, day 3, day 5, and day 7 after the implantation of fiducial markers to detect the motion of markers in the tumor.
Results: A total of 23 fiducial markers for 10 patients were implanted. The success rate was 100%(23/23). One patient developed mild elevation of elevated serum amylase (Grade 1), other complications were not observed. Taking the markers position on day 7 as reference, fiducial marker movement rate was 4.35% (1/23 ), 4.35% (1/23 ) and 0.0% (0/23 ) on Day 1, Day 3 and Day 5.
Conclusion: This new method of CT-guided and 3D-printing template-assisted implantation of fiducial markers for SBRT in the pancreatic carcinoma is feasible with high success rate and safety. The appropriate time interval between fiducial marker implantation and the CT simulation is recommended to be at least 5 days after fiducial marker implantation.